6.67 USD
+0.25
3.89%
At close Apr 30, 4:00 PM EDT
After hours
6.70
+0.03
0.45%
1 day
3.89%
5 days
-10.95%
1 month
4.06%
3 months
-25.97%
6 months
-32.22%
Year to date
-22.17%
1 year
54.04%
5 years
-63.21%
10 years
-95.69%
 

About: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Employees: 1,992

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]

44% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 54

5.49% more ownership

Funds ownership: 58.55% [Q3] → 64.04% (+5.49%) [Q4]

5% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 41

3% less funds holding

Funds holding: 233 [Q3] → 226 (-7) [Q4]

29% less call options, than puts

Call options by funds: $65.9M | Put options by funds: $92.9M

30% less capital invested

Capital invested by funds: $1.19B [Q3] → $825M (-$361M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for NVAX.

Financial journalist opinion

Based on 22 articles about NVAX published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Neutral
PRNewsWire
1 day ago
Novavax Appoints Charles Newton to Board of Directors
GAITHERSBURG, Md. , April 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director.
Novavax Appoints Charles Newton to Board of Directors
Negative
Reuters
5 days ago
FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports
Federal regulators are asking Novavax to complete an additional clinical trial on its Covid-19 vaccine after previously delaying approval, the Wall Street Journal reported on Friday, citing people familiar with the matter.
FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports
Negative
WSJ
5 days ago
FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot
A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say.
FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot
Neutral
Reuters
6 days ago
Insight: As FDA delays Novavax' COVID vaccine approval, patients fight back
Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might still win approval after Health Secretary Robert F. Kennedy Jr cast doubt on its efficacy.
Insight: As FDA delays Novavax' COVID vaccine approval, patients fight back
Positive
Zacks Investment Research
6 days ago
Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?
Positive
Benzinga
1 week ago
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
Novavax, Inc. NAVX stock traded higher on Wednesday.
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
Positive
Proactive Investors
1 week ago
Novavax shares jump as FDA signals path to COVID vaccine approval
Novavax, Inc. (NASDAQ:NVAX) shares surged more than 16% after the company shared a positive update on its COVID-19 vaccine, which it believes is “approvable” based on its conversations with the US Food and Drug Administration (FDA). The company said the FDA has requested additional data on the vaccine as part of a post-marketing commitment (PMC).
Novavax shares jump as FDA signals path to COVID vaccine approval
Positive
Zacks Investment Research
1 week ago
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Neutral
Reuters
1 week ago
FDA asks Novavax for commitment on post-approval studies for COVID vaccine
Novavax said on Wednesday the U.S. Food and Drug Administration has sought a commitment from the COVID-19 vaccine maker for additional clinical data if it approves the shot.
FDA asks Novavax for commitment on post-approval studies for COVID vaccine
Charts implemented using Lightweight Charts™